NeoImmuneTech Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Luke Yun Oh

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	1.8yrs

Actualizaciones recientes de la dirección

Recent updates

Will NeoImmuneTech (KOSDAQ:950220) Spend Its Cash Wisely?

Mar 22

CEO

Luke Yun Oh

less than a year

Permanencia

Dr. Luke Yun Suk Oh Ph. D. is President of NeoImmuneTech, Inc. from January 15, 2024 and serves as its Chief Executive Officer since March 29, 2024 and serves as its Chairman since 2024. Dr. Oh is an exper...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Luke Yun Oh	President	less than a year	sin datos	sin datos
Tae Woo Kim	Chief Financial Officer	no data	sin datos	0% ₩ 0
Goongjin Nam	Chief Operating Officer	4.4yrs	sin datos	0% ₩ 0
Byung Lee	Chief Scientific Officer	3.3yrs	sin datos	0% ₩ 0

3.3yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de A950220 se considera experimentado (3.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Luke Yun Oh	President	less than a year	sin datos	sin datos
Rafi Ahmed	Member of Scientific Advisory Board	4.6yrs	sin datos	sin datos
Soo-Hyoung Kang	Director	no data	sin datos	sin datos
Jin-Hyoung Kang	Director	3.1yrs	sin datos	sin datos
Sung-June Hong	Director	less than a year	sin datos	sin datos
Richard Kim	Member of Scientific Advisory Board	1.8yrs	sin datos	sin datos
Keith Watson	Member of Scientific Advisory Board	1.8yrs	sin datos	sin datos
Hyunseok Kang	Member of Scientific Advisory Board	1.8yrs	sin datos	sin datos
Young Chae	Member of Scientific Advisory Board	1.8yrs	sin datos	sin datos
Benny Chen	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Su-Hyung Park	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Choonggoo Kang	Director	less than a year	sin datos	sin datos

1.8yrs

Permanencia media

Junta con experiencia: La junta directiva de A950220 no se considera experimentada (1.7 años de permanencia promedio), lo que sugiere una nueva junta directiva.

NeoImmuneTech Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

NeoImmuneTech, Inc. Appoints Luke Oh as President

Neoimmunetech, Inc. Appoints Benny J. Chen and Su-Hyung Park to Its Scientific Advisory Board

No independent directors

NeoImmuneTech, Inc. Appoints New Members to its Scientific Advisory Board

Recent updates

NeoImmuneTech's New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors (CPI) in Immuno-Oncology

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

Will NeoImmuneTech (KOSDAQ:950220) Spend Its Cash Wisely?

New minor risk - Share price stability

NeoImmuneTech, Inc. Appoints Luke Oh as President

Fda Grants Orphan Drug Designation to Neoimmunetech's Nt-I7 for the Treatment of Acute Radiation Syndrome

New minor risk - Share price stability

Neoimmunetech, Inc. Appoints Benny J. Chen and Su-Hyung Park to Its Scientific Advisory Board

No independent directors

New Evidence of NeoImmuneTech's NT-I7 Clinical Efficacy in Combination with Pembrolizumab in Relapsed/Refractory (R/R) Gastrointestinal Tumors

NeoImmuneTech, Inc. Appoints New Members to its Scientific Advisory Board

NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity

NeoImmuneTech, Inc.'s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors

No independent directors

Neoimmunetech Demonstrates Nt-I7’S Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine At Aacr 2022

NeoImmuneTech, Inc. Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 Checkpoint Inhibitor in High-Risk Skin Cancers

NeoImmuneTech, Inc. Announces the Publication of Preclinical Data Evaluating Lead Asset NT-I7

NeoImmuneTech, Inc. announced that it has received $4.7 million in funding from Hefei SPARK Venture Capital Management Co., Ltd., Kindstar Global (Beijing) Technology, Inc.

NeoImmuneTech, Inc. Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting

Neoimmunetech to Present At Society for Neuro-Oncology

NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection

NeoImmuneTech, Inc. Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)

NeoImmuneTech, Inc. Announces First Patient Dosed in the Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media